Opinion|Videos|February 10, 2025
Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients
Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Advertisement
Video content above is prompted by the following:
- How do the treatment options evolve as a child ages?
- FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
- How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
- Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.
Advertisement
Related to this article
Johns Hopkins Children's Center experts outline pedestrian, burn, allergy, anxiety, and candy guidance pediatricians can share before Halloween.
Pumpkin carving accounts for 55% of Halloween ED injuries; AAOS outlines prevention tips for carving, costumes, and trick-or-treating.
NHIS data show the share of US children aged 5 to 17 years ever diagnosed with ADHD climbed from 9.9% in 2019 to 13.8% in 2025.
A proposed rule would revise iodine, manganese, and vitamin A and D levels in infant formula and reaffirm 4 other nutrient specifications.
A review of 93 studies links pediatric home-based hospice and palliative care to fewer hospital days, lower costs, and better family QOL.
With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.
Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.
Self-harm risk in ADHD peaked in the 90 days before medication initiation and declined once treatment began, a 5-system analysis found.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FAQ: What should clinicians know about congenital measles?
2
CDC: ADHD diagnoses in US children rose to 13.8% from 2019 to 2025
3
Pumpkin carving drives over half of Halloween ED injuries
4
Experts share pediatric Halloween safety guidance
5